Mereo BioPharma
MREO
53 hedge funds and large institutions have $84.3M invested in Mereo BioPharma in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 11 closing their positions.
2,668% more call options, than puts
Call options by funds: $775K | Put options by funds: $28K
96% more capital invested
Capital invested by funds: $43M → $84.3M (+$41.3M)
0.59% more ownership
Funds ownership: 9.73% → 10.32% (+0.59%)
9% less funds holding
Funds holding: 58 → 53 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
57% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$6.42M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$4.12M |
| 3 |
6CM
683 Capital Management
New York
|
+$3.94M |
| 4 |
Alkeon Capital Management
New York
|
+$1.57M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$5.48M |
| 2 |
Millennium Management
New York
|
-$1.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.48M |
| 4 |
Citigroup
New York
|
-$799K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
-$708K |
MREO Hedge Fund Activity: Q2 2023 in Review
53 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2023, worth a combined $84.3M — up 96% from $43M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MREO and 6 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 9 added.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $6.42M. The largest seller was OrbiMed, exiting entirely with an estimated $5.48M sold.
- 53 institutional investors held Mereo BioPharma (MREO) as of Q2 2023, down from 58 in Q1 2023.
- Funds reported $84.3M of Mereo BioPharma stock for Q2 2023, up 96% quarter-over-quarter.
- 6 funds opened new Mereo BioPharma positions in Q2 2023 and 11 closed out, a net change of -5 holders.
- The largest Mereo BioPharma buyer in Q2 2023 was Mangrove Partners, an estimated $6.42M added.
- The largest Mereo BioPharma seller in Q2 2023 was OrbiMed, an estimated $5.48M sold.
Based on aggregated 13F filings for Q2 2023.